Corporate ActionJun 10, 2026, 04:06 PM
Humacyte Commences Underwritten Public Offering of Common Stock
AI Summary
Humacyte, Inc. announced the commencement of an underwritten public offering of its common stock. The company intends to grant the underwriters an option to purchase up to an additional 15% of the shares sold for a period of 30 days. Humacyte plans to use the net proceeds to fund the commercialization of Symvess, support the planned Biologics License Application supplement filing for a hemodialysis indication, advance its product pipeline, and for general corporate purposes.
Key Highlights
- Humacyte commenced an underwritten public offering of its common stock.
- Underwriters have a 30-day option to purchase up to an additional 15% of shares.
- Proceeds will fund the commercialization of Symvess and a planned BLA supplement filing.
- Funds are also allocated for pipeline development and general corporate purposes.
- Barclays, BTIG, and Titan Partners are acting as joint book-running managers for the offering.
Price Impact
More from HUMA